Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 195

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 195
---
 |                     67 |         122 |         131 |              715 |
| Total contractual obligations and other commitments                                                                                        | 28,585 |                  6,790 |       6,999 |       4,659 |           10,137 |
| Undrawn general-purpose credit facilities                                                                                                  |  8,000 |                      — |       4,000 |           — |            4,000 |

(a) See Note D.17.1. to our consolidated financial statements, included at Item 18. of this annual report. (b) See Note D.17.2. to our consolidated financial statements, included at Item 18. of this annual report. (c) See Note D.21.1. to our consolidated financial statements, included at Item 18. of this annual report. (d) These comprise irrevocable commitments to suppliers of (i) property, plant and equipment, net of down payments (see Note D.3. to our consolidated financial statements, included at Item 18. of this annual report) and (ii) goods and services. (e) This line includes all milestone payments on projects regarded as reasonably possible, i.e. on projects in the development phase. (f) See Note D.18. to our consolidated financial statements, included at Item 18. of this annual report. (g) See Note D.19.1. to our consolidated financial statements, included at Item 18. of this annual report. The table above does not include ongoing annual employer’s contributions to plan assets, estimated at € 77 million for 2024. We may have payments due to our current or former research and development partners under collaboration agreements. These agreements typically cover multiple products, and give us the option to participate in development on a product-by- product basis. When we exercise our option with respect to a product, we pay our collaboration partner a fee and receive intellectual property rights to the product in exchange. We are also generally required to fund some or all of the development costs for the products that we select, and to make payments to our partners when those products reach development milestones. We have entered into collaboration agreements under which we have rights to acquire products or technology from third parties through the acquisition of shares, loans, license agreements, joint development, co-marketing and other contractual arrangements. In addition to upfront payments on signature of the agreement, our contracts frequently require us to make payments contingent upon the completion of development milestones by our alliance